Kineta shares are trading higher after the company announced that it entered into an exclusivity and right of first offer agreement with TuHURA Biosciences to grant the immune-oncology company exclusive rights to acquire its Anti-VISTA antibody.
Portfolio Pulse from Benzinga Newsdesk
Kineta shares are trading higher after announcing an exclusivity and right of first offer agreement with TuHURA Biosciences for its Anti-VISTA antibody.
July 08, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kineta shares are trading higher following the announcement of an exclusivity and right of first offer agreement with TuHURA Biosciences for its Anti-VISTA antibody.
The agreement with TuHURA Biosciences is a significant development for Kineta, as it grants exclusive rights to acquire its Anti-VISTA antibody. This could lead to future revenue streams and strategic advantages in the immune-oncology market, driving investor optimism and pushing the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100